Autopsy report · NCT03119467

Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas

“Study has been stopped after reviewing PK and safety results”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 2 years 7 months before it stopped.
• 21 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Rhizen Pharmaceuticals SA

Sponsor type

Industry

Conditions

Lymphoma

Interventions

RP4010

Participants

21

Sites

11

Countries

Australia, United States

Trials that died the same way

• Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection
  “The study was stopped due to safety concerns” (76% match in meaning)
• Stroke With Transfusions Changing to Hydroxyurea
  “The study has been stopped due to safety and futility concerns.” (75% match in meaning)
• Nasal High-frequency Jet Ventilation (nHFJV) Following Extubation in Preterm Infants
  “Study stopped due to safety reasons.” (73% match in meaning)
• An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis
  “The study was stopped due to a non-clinical safety finding.” (72% match in meaning)
• An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
  “As of 31 JAN 2018, the study was terminated by the sponsor due to PK variability.” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.